GO:1904283 negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I: Immune Evasion Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1904283 describes any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation of endogenous peptide antigen via MHC class I.
• This negative regulation is a key immune evasion strategy used by viruses and tumors to avoid CD8+ T cell recognition.
• The HIV-1 Gag PTAP sequence regulates Gag ubiquitination and MHC class I antigen presentation, providing a model for how viral proteins can downregulate this pathway.
• MicroRNAs and transcripts can interact to modulate antigen presentation pathways, as shown in bovine leukemia virus exposure studies.
• GINS4 has been identified as a prognostic immune-related biomarker in esophageal squamous cell carcinoma and other cancers, linking DNA replication factors to immune regulation.
• Studying GO:1904283 requires CRISPR knockout, point mutation, knock-in, and overexpression models combined with immunopeptidomics and functional T cell assays [2,3].
Description
The Gene Ontology term GO:1904283, negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I, defines a biological process that dampens the presentation of intracellular peptides to CD8+ T cells. This process is critical for immune homeostasis but is frequently hijacked by pathogens and tumors to escape immune surveillance. Understanding the molecular players that mediate this negative regulation is essential for developing immunotherapies and vaccines. Recent studies have highlighted diverse mechanisms, from viral protein motifs that alter ubiquitination to microRNA-mediated transcript modulation, all converging on reduced MHC class I antigen presentation [1,2]. Researchers studying this term aim to identify the genes, regulatory networks, and post-translational modifications that control this pathway, with the ultimate goal of restoring immune recognition in disease settings.
negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I At A Glance
| GO ID | GO:1904283 |
|---|---|
| GO term | negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I |
| Ontology | biological_process |
| Synonym | inhibition of antigen processing and presentation of endogenous peptide antigen via MHC class I; downregulation of endogenous peptide antigen processing and presentation via MHC class I |
| Major function | Suppression of CD8+ T cell activation by reducing MHC class I presentation of endogenous peptides |
| Related process | Antigen processing and presentation of endogenous peptide antigen via MHC class I (GO:0019883) |
| Regulatory direction | Negative (inhibitory) |
| Taxonomic range | Eukaryota, including viral and tumor contexts |
| Example regulators | HIV-1 Gag PTAP motif, microRNAs, GINS4 |
What Is GO:1904283?
GO:1904283 encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation of endogenous peptide antigen via MHC class I. In other words, it is the negative regulation of the cellular pathway that normally takes intracellular proteins, degrades them into peptides, and displays those peptides on the cell surface via MHC class I molecules for recognition by CD8+ T cells. This term covers inhibition at any step, including peptide generation, transport, MHC class I loading, or surface expression.
Why Is negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I Important in Cell Biology?
GO:1904283 is important because it represents a central mechanism of immune evasion used by viruses and cancers to escape CD8+ T cell-mediated killing. By understanding how this negative regulation occurs, researchers can design interventions to block it, thereby enhancing antitumor and antiviral immunity. Moreover, this term is relevant to autoimmune diseases where excessive negative regulation might contribute to immune tolerance, and to vaccine development where transient inhibition could improve immunogenicity.
• Viral immune evasion: HIV-1 and other viruses use motifs like PTAP to downregulate MHC class I presentation.
• Cancer immunotherapy: Tumors often suppress antigen presentation; targeting this negative regulation can restore T cell recognition.
• Autoimmunity: Defects in negative regulation may lead to excessive T cell activation and autoimmunity.
• Vaccine design: Modulating this pathway can enhance or prolong antigen presentation for better vaccines.
• Biomarker discovery: Genes like GINS4 are linked to immune-related prognosis in cancers.
• Basic immunology: Understanding how cells fine-tune MHC class I levels is fundamental to immune regulation.
• Therapeutic targets: Enzymes and ubiquitin ligases involved are potential drug targets.
• MicroRNA therapeutics: miRNAs that modulate this pathway could be used as therapeutics.
• Personalized medicine: Patient tumors with high negative regulation may benefit from checkpoint inhibitors.
• CRISPR screening: Genome-wide screens can identify novel regulators of this process.
What Happens During negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I?
Initiation of negative regulation
In simple terms: Something starts the process of shutting down antigen presentation.
Negative regulation can be initiated by viral proteins, cellular stress, or microRNAs that target components of the MHC class I pathway [1,2]. For example, the HIV-1 Gag PTAP sequence regulates Gag ubiquitination and subsequently affects MHC class I antigen presentation. MicroRNAs can also interact with transcripts to modulate this pathway, as seen in bovine leukemia virus exposure.
Inhibition of peptide generation
In simple terms: The production of peptides from proteins is reduced.
Negative regulators can interfere with proteasomal degradation or peptide trimming by aminopeptidases, reducing the pool of endogenous peptides available for MHC class I loading. This step is often targeted by viral proteins that alter ubiquitination pathways.
Blockade of peptide transport and loading
In simple terms: Peptides are prevented from reaching MHC class I molecules.
Negative regulation can inhibit the transporter associated with antigen processing (TAP) or tapasin, preventing peptide loading onto MHC class I in the endoplasmic reticulum. This leads to unstable MHC class I molecules and reduced surface presentation.
Downregulation of MHC class I surface expression
In simple terms: MHC class I molecules are removed from the cell surface.
Ultimately, negative regulation often results in decreased MHC class I surface levels through enhanced endocytosis or degradation. This reduces CD8+ T cell recognition and allows infected or transformed cells to evade immune attack.
Key Genes Involved in GO:1904283 negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I
The following genes and proteins are involved in the negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HIV-1 Gag | Contains PTAP motif that regulates ubiquitination and MHC class I antigen presentation | Model for viral immune evasion; studies use PTAP mutants to dissect mechanism |
| GINS4 | DNA replication factor; prognostic immune-related biomarker in cancers | Linked to immune regulation; potential target for cancer immunotherapy |
| MicroRNAs (e.g., from BLV) | Modulate transcripts involved in antigen presentation | Studied in bovine leukemia virus exposure; potential therapeutic targets |
| Ubiquitin ligases | Mediate ubiquitination of MHC class I or pathway components | Targets for enhancing antigen presentation |
| Proteasome subunits | Generate peptides for MHC class I | Negative regulation may alter proteasome composition |
| TAP1/TAP2 | Transport peptides into ER | Inhibition reduces peptide supply |
| Tapasin | Peptide loading onto MHC class I | Downregulation impairs presentation |
| ERAP1 | Trim peptides for MHC class I | Negative regulation may affect trimming |
| MHC class I heavy chain | Presents peptides to CD8+ T cells | Surface downregulation is a key endpoint |
| Beta-2-microglobulin | MHC class I light chain | Stability and surface expression |
| CD8+ T cells | Recognize MHC class I-peptide complexes | Functional readout of negative regulation |
| NF-kB | Transcription factor regulating immune genes | May be modulated during negative regulation |
| Interferon-gamma | Upregulates MHC class I | Counteracts negative regulation |
| STAT1 | Signaling downstream of IFN | Affects antigen presentation |
| IRF1 | Transcription factor for MHC class I | Regulated by negative pathways |
| BLV transcripts | Viral RNAs that interact with miRNAs | Model for retroviral immune evasion |
How Is negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I Regulated?
The negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I is itself controlled by various cellular and viral factors. For instance, the HIV-1 Gag PTAP sequence regulates Gag ubiquitination, which in turn affects MHC class I antigen presentation. MicroRNAs can interact with transcripts to modulate this pathway, as demonstrated in bovine leukemia virus exposure studies. Additionally, immune-related biomarkers like GINS4 may influence the tumor immune microenvironment and indirectly regulate antigen presentation. These regulatory layers provide multiple entry points for therapeutic intervention.
negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HIV-1 Gag | HIV/AIDS immune evasion | Knockout of PTAP motif in HIV-1 provirus; T cell assays |
| GINS4 | Esophageal squamous cell carcinoma and other cancers | CRISPR knockout in cancer cell lines; immunopeptidomics |
| MicroRNAs (BLV) | Bovine leukemia virus infection | Overexpression of miRNAs in bovine cells; transcriptomics |
| Ubiquitin ligases | Cancer and viral infections | Knockout or point mutation; MHC class I surface staining |
| TAP1/TAP2 | Immune evasion in cancers | Knockout in tumor cells; peptide transport assays |
Viral Infections and Immune Evasion
Many viruses, including HIV-1, have evolved mechanisms to negatively regulate MHC class I antigen presentation to evade CD8+ T cell responses. The HIV-1 Gag PTAP sequence is a well-characterized example that regulates Gag ubiquitination and downstream antigen presentation. Understanding these viral strategies can inform vaccine design and antiviral therapies.
Cancer Immunotherapy
Tumors often downregulate MHC class I antigen presentation to escape immune surveillance. Genes such as GINS4 have been identified as prognostic immune-related biomarkers in esophageal squamous cell carcinoma and other cancers, suggesting a link between DNA replication factors and immune evasion. Targeting the negative regulation of antigen presentation could enhance the efficacy of immune checkpoint inhibitors.
Autoimmune and Inflammatory Diseases
Dysregulated negative regulation of antigen presentation may contribute to autoimmune diseases by altering the balance of T cell activation. MicroRNA-mediated modulation of antigen presentation pathways, as seen in bovine leukemia virus exposure, highlights the complexity of these regulatory networks. Further research is needed to link specific negative regulators to autoimmune conditions.
From negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate MHC class I presentation? | CRISPR knockout of gene X in antigen-presenting cells, followed by MHC class I surface staining and T cell activation assays |
| What is the role of a specific phosphorylation site in negative regulation? | Point mutation (e.g., serine-to-alanine) knock-in via CRISPR |
| How does a viral motif like PTAP mediate immune evasion? | Knock-in of PTAP motif into a reporter virus; ubiquitination and antigen presentation assays |
| Can overexpression of a microRNA downregulate antigen presentation? | Overexpression of miRNA in target cells; transcriptomics and MHC class I flow cytometry |
| What is the interactome of a negative regulator? | Tagged knock-in (e.g., FLAG or HA) followed by immunoprecipitation-mass spectrometry |
| Can we identify novel regulators via genome-wide screening? | CRISPR library screening with MHC class I surface readout |
How to Study the negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Immunopeptidomics | Peptides presented by MHC class I | Quantify changes in antigen presentation after genetic perturbation |
| Flow cytometry | MHC class I surface expression | Screen for regulators of antigen presentation |
| T cell activation assay | Functional antigen presentation | Validate negative regulators in co-culture |
| RNA-seq | Transcriptome changes | Identify pathways co-regulated with antigen presentation |
| Small RNA-seq | MicroRNA expression | Discover miRNAs that modulate antigen presentation |
| CRISPR library screening | Genome-wide regulators | Identify novel negative regulators of MHC class I |
| Immunoprecipitation-mass spectrometry | Protein interactions | Map interactome of negative regulators |
| Ubiquitination assays | Post-translational modifications | Study PTAP-mediated regulation |
Immunopeptidomics
Immunopeptidomics uses mass spectrometry to identify peptides presented by MHC class I molecules. This method can quantify changes in the immunopeptidome upon negative regulation, revealing which peptides are lost.
Flow Cytometry for MHC Class I Surface Expression
Flow cytometry with antibodies against MHC class I can measure surface levels, a direct readout of negative regulation. This is often used after CRISPR knockout or overexpression of candidate genes.
T Cell Activation Assays
Co-culture of target cells with peptide-specific CD8+ T cells followed by cytokine release or cytotoxicity assays measures functional antigen presentation. Reduced T cell activation indicates negative regulation.
Transcriptomics and MicroRNA Profiling
RNA-seq and small RNA-seq can identify changes in transcripts and microRNAs that correlate with negative regulation, as shown in bovine leukemia virus exposure studies.
How CRISPR Can Be Used to Study GO:1904283 negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I
Knockout
CRISPR knockout is used to delete candidate negative regulators and assess whether MHC class I presentation increases. For example, knocking out a ubiquitin ligase that targets MHC class I may restore surface expression and T cell recognition.
Point Mutation
Point mutations can be introduced to dissect specific residues, such as the PTAP motif in HIV-1 Gag, to determine their role in ubiquitination and antigen presentation. This allows precise structure-function analysis.
Knock-in
Knock-in of tagged versions of genes (e.g., FLAG, HA) enables immunoprecipitation and localization studies. Knock-in of viral motifs into reporter viruses helps model immune evasion.
Overexpression
Overexpression of microRNAs or negative regulators can be achieved via CRISPR activation or lentiviral delivery. This is useful for studying gain-of-function effects on antigen presentation.
How EDITGENE Supports negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I Research
Researchers studying negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I-related genes often need to determine whether a candidate gene is causally involved in suppressing MHC class I presentation. This requires precise genetic models to manipulate gene expression and function, followed by functional readouts such as immunopeptidomics and T cell assays. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I research.
Frequently Asked Questions About negative regulation of antigen processing and presentation of endogenous peptide antigen via MHC class I
What is GO:1904283?
GO:1904283 is a Gene Ontology term for any process that stops, prevents, or reduces the frequency, rate, or extent of antigen processing and presentation of endogenous peptide antigen via MHC class I.
What genes are involved in negative regulation of MHC class I antigen presentation?
Genes include HIV-1 Gag (via PTAP motif), GINS4, microRNAs, ubiquitin ligases, and TAP1/TAP2 [1,2,3].
How does HIV-1 evade MHC class I presentation?
The HIV-1 Gag PTAP sequence regulates Gag ubiquitination and MHC class I antigen presentation, contributing to immune evasion.
What is the role of GINS4 in cancer immunity?
GINS4 is a prognostic immune-related biomarker in esophageal squamous cell carcinoma and other cancers, potentially influencing antigen presentation.
Can microRNAs regulate antigen presentation?
Yes, microRNAs can interact with transcripts to modulate antigen presentation pathways, as shown in bovine leukemia virus exposure.
What methods study negative regulation of antigen presentation?
Immunopeptidomics, flow cytometry, T cell activation assays, RNA-seq, and CRISPR screens are commonly used [1,2,3].
How can CRISPR help study GO:1904283?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of candidate genes to test their role in negative regulation.
What diseases are linked to negative regulation of MHC class I?
Viral infections (e.g., HIV), cancer immune evasion, and potentially autoimmune diseases [1,2,3].
What is the PTAP motif?
PTAP is a sequence in HIV-1 Gag that regulates ubiquitination and MHC class I antigen presentation.
How does negative regulation affect CD8+ T cells?
By reducing MHC class I-peptide complexes on the cell surface, negative regulation diminishes CD8+ T cell recognition and activation.
Conclusion
GO:1904283 represents a critical biological process by which cells and pathogens suppress MHC class I antigen presentation to evade CD8+ T cell immunity. Key regulators such as the HIV-1 Gag PTAP motif, microRNAs, and GINS4 have been identified, providing insights into viral immune evasion and cancer immunotherapy [1,2,3]. Continued research using CRISPR models and advanced immunopeptidomics will uncover new therapeutic targets to modulate this pathway.
References
- 1. Ma H et al.. 2022. Expression Profiles and Interaction of MicroRNA and Transcripts in Response to Bovine Leukemia Virus Exposure.. Front Vet Sci 9:887560 PMID: 35928115
- 2. Hahn S et al.. 2011. The PTAP sequence within the p6 domain of human immunodeficiency virus type 1 Gag regulates its ubiquitination and MHC class I antigen presentation.. J Immunol 186(10):5706-18 PMID: 21482733
- 3. Jin D et al.. 2022. GINS4 might be a novel prognostic immune-related biomarker of not only esophageal squamous cell carcinoma and other cancers.. BMC Med Genomics 15(1):75 PMID: 35365175
